Pfizer CEO Plugs HIV Pipeline Agent At Presidential Advisory Council Meeting
This article was originally published in The Pink Sheet Daily
Executive Summary
The CCR5 inhibitor could be on the market "in a couple of years," CEO McKinnell says. He praises industry efforts to develop fixed-dose HIV/AIDS combinations but acknowledges that such partnerships can be "four times as difficult" as a developing a standalone product.